Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

Journal Article (Journal Article)

Adoptive cell therapy with tumor-targeted T cells is a promising approach to cancer therapy. Enhanced clinical outcome using this approach requires conditioning regimens with total body irradiation, lymphodepleting chemotherapy, and/or additional cytokine support. However, the need for prior conditioning precludes optimal application of this approach to a significant number of cancer patients intolerant to these regimens. Herein, we present preclinical studies demonstrating that treatment with CD19-specific, chimeric antigen receptor (CAR)-modified T cells that are further modified to constitutively secrete IL-12 are able to safely eradicate established disease in the absence of prior conditioning. We demonstrate in a novel syngeneic tumor model that tumor elimination requires both CD4(+) and CD8(+) T-cell subsets, autocrine IL-12 stimulation, and subsequent IFNγ secretion by the CAR(+) T cells. Importantly, IL-12-secreting, tumor-targeted T cells acquire intrinsic resistance to T regulatory cell-mediated inhibition. Based on these preclinical data, we anticipate that adoptive therapy using CAR-targeted T cells modified to secrete IL-12 will obviate or reduce the need for potentially hazardous conditioning regimens to achieve optimal antitumor responses in cancer patients.

Full Text

Duke Authors

Cited Authors

  • Pegram, HJ; Lee, JC; Hayman, EG; Imperato, GH; Tedder, TF; Sadelain, M; Brentjens, RJ

Published Date

  • May 3, 2012

Published In

Volume / Issue

  • 119 / 18

Start / End Page

  • 4133 - 4141

PubMed ID

  • 22354001

Pubmed Central ID

  • PMC3359735

Electronic International Standard Serial Number (EISSN)

  • 1528-0020

Digital Object Identifier (DOI)

  • 10.1182/blood-2011-12-400044


  • eng

Conference Location

  • United States